28th October 2010

Mirada Medical Signs Agreement with Moffitt Cancer Center to Develop New Technologies for Radiotherapy Planning

Mirada Medical Limited,the fast growing international company focused on advanced oncology imaging, announced today that it has signed an agreement with Moffitt Cancer Center, Tampa, FL, one of the USA’s top centers for cancer treatment and oncology research. The initial agreement allows the Oxford, UK, based company to evaluate and understand the Moffitt technology, and to potentially develop clinical applications which will encapsulate and build upon the anatomical atlases which have been developed by Dr S. Finkelstein, et al. Dr Finkelstein’s sarcoma atlas has been recognized by the Radiation Therapy Oncology Group (RTOG). The agreement extends to other anatomical regions, including the liver. Prototypes of the combined technology will be on show the ASTRO meeting (San Diego 31st October to 4th November, booth #1813) said Mirada Medical, though the company pointed out that these developments are early stage and not currently available for sale in the USA or elsewhere. Commenting on the joint development agreement, the Chair of the Moffitt Radiation Oncology Department, Dr Craig Stevens, said: “We are very excited about the opportunity to work with Mirada Medical. Their expertise and ours complement extremely well. We look forward to a long productive relationship.” Ray Carpenter, Senior Licensing Manager at Moffitt Cancer Center, commented: “We are very pleased that, through this agreement, we begin a collaboration with an internationally accomplished company, Mirada Medical, to help develop the important research discovered here at Moffitt into valuable tools useful for the prevention and cure of cancer.” Hugh Bettesworth, CEO of Mirada Medical, said: “Mirada Medical’s philosophy is to ensure that the latest and most effective information technologies are available to the widest possible user base within the clinical community. We firmly believe that to do this, we need to innovate within our own company, but also be prepared to work with innovators working in clinical research elsewhere. The fact that something is or is not invented here is not our prime concern. Our mission is to discover the leading technologies and make these available to our growing user base. I expect our collaboration with Moffitt Cancer Center to provide a perfect example of this.”